Effect of Oral Supplementation With Curcumin (Turmeric) in Patients With Proteinuric Chronic Kidney Disease

Phase 3

Completed

• Conditions: Proteinuria
• Interventions: Drug: Curcumin

• Registration Number: NCT01831193
• Lead Sponsor: Instituto Nacional de Cardiologia Ignacio Chavez

Brief Summary

The purpose of this study is to determine if the oral supplementation with curcumin reduces proteinuria in patients with chronic kidney disease regardless the ethiology.

Detailed Description

Curcumin is a potent antioxidant found in extracts of the rhizome of the plant Curcuma longa L.

Different studies have demonstrated that curcumin has potent biological activity and therefore is an effective therapeutic agent for the treatment of various ailments.

This compound acts as a bifunctional antioxidant:

ه is capable of reacting directly with highly reactive oxygen species. ه acts indirectly by its ability to induce the expression of various cytoprotective proteins through Keap1/Nrf2/ARE pathway.

Although RAAS blockade is the cornerstone to prevent the progression of proteinuric nephropathy, a significant number of patients remained with proteinuria and progress to end-stage renal disease.

Due to the low cost and few side effects of curcumin, this could become an adjuvant treatment of proteinuric nephropathy purposes attenuate the progression of chronic kidney disease.

Study Timeline

• Study Start: 2013-02
• Study First Submitted: 2013-04-09
• Study First Submitted QC: 2013-04-10
• Study First Posted: 2013-04-15
• Primary Completion: 2014-04
• Study Completion: 2014-04
• Status Verified: 2014-07
• Last Update Submitted: 2014-07-23
• Last Update Posted: 2014-07-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Diagnosis of proteinuric chronic kidney disease with 1g or more of proteins in a daily recollection.
• Individuals taking Angiotensin II Receptor Blocker or ACE inhibitors in monotherapy with maximum dose or in combination.

Exclusion Criteria

• Hepatic damage.
• Malignancy.
• Pregnancy.
• Peritoneal or hemodialysis.
• Organ transplantation.
• Heart failure classification III or IV (New York Heart Association).
• History of chemotherapy within 2 years prior to screening.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Diabetic	Curcumin	-
Non-diabetic	Curcumin	-

Primary Outcome Measures

Name	Time	Method
Change in proteinuria	8 weeks

Trial Locations

Locations (1)

Instituto Nacional de Cardiologia Ignacio Chavez; 🇲🇽 Mexico city, DF, Mexico